vs
博思艾伦汉密尔顿（BAH）与博士伦（BLCO）财务数据对比。点击上方公司名可切换其他公司
博思艾伦汉密尔顿的季度营收约是博士伦的1.9倍（$2.6B vs $1.4B），博思艾伦汉密尔顿净利率更高（7.6% vs -4.1%，领先11.8%），博士伦同比增速更快（9.8% vs -10.2%），博思艾伦汉密尔顿自由现金流更多（$248.0M vs $60.0M），过去两年博士伦的营收复合增速更高（13.1% vs -2.8%）
博思艾伦汉密尔顿控股集团是美国知名专业服务企业，深耕数字化转型与人工智能领域，为公共部门、私营机构及非营利组织提供咨询、分析与工程服务，总部位于弗吉尼亚州麦克莱恩，属华盛顿大都会区，在全球另设有80个办事处。
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
BAH vs BLCO — 直观对比
营收规模更大
BAH
是对方的1.9倍
$1.4B
营收增速更快
BLCO
高出20.0%
-10.2%
净利率更高
BAH
高出11.8%
-4.1%
自由现金流更多
BAH
多$188.0M
$60.0M
两年增速更快
BLCO
近两年复合增速
-2.8%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.6B | $1.4B |
| 净利润 | $200.0M | $-58.0M |
| 毛利率 | 51.9% | — |
| 营业利润率 | 8.8% | 8.0% |
| 净利率 | 7.6% | -4.1% |
| 营收同比 | -10.2% | 9.8% |
| 净利润同比 | 7.0% | -1833.3% |
| 每股收益（稀释后） | $1.63 | $-0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BAHBLCO
| Q4 25 | $2.6B | $1.4B | ||
| Q3 25 | $2.9B | $1.3B | ||
| Q2 25 | $2.9B | $1.3B | ||
| Q1 25 | $3.0B | $1.1B | ||
| Q4 24 | $2.9B | $1.3B | ||
| Q3 24 | $3.1B | $1.2B | ||
| Q2 24 | $2.9B | $1.2B | ||
| Q1 24 | $2.8B | $1.1B |
净利润BAHBLCO
| Q4 25 | $200.0M | $-58.0M | ||
| Q3 25 | $175.0M | $-28.0M | ||
| Q2 25 | $271.0M | $-62.0M | ||
| Q1 25 | $192.7M | $-212.0M | ||
| Q4 24 | $186.9M | $-3.0M | ||
| Q3 24 | $390.1M | $4.0M | ||
| Q2 24 | $165.2M | $-151.0M | ||
| Q1 24 | $128.0M | $-167.0M |
毛利率BAHBLCO
| Q4 25 | 51.9% | — | ||
| Q3 25 | 53.6% | — | ||
| Q2 25 | 51.3% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 55.2% | — | ||
| Q3 24 | 56.7% | — | ||
| Q2 24 | 53.4% | — | ||
| Q1 24 | 54.7% | — |
营业利润率BAHBLCO
| Q4 25 | 8.8% | 8.0% | ||
| Q3 25 | 9.8% | 7.4% | ||
| Q2 25 | 8.8% | -0.9% | ||
| Q1 25 | 9.2% | -7.3% | ||
| Q4 24 | 10.0% | 6.8% | ||
| Q3 24 | 17.4% | 3.6% | ||
| Q2 24 | 8.7% | 2.1% | ||
| Q1 24 | 9.5% | 0.5% |
净利率BAHBLCO
| Q4 25 | 7.6% | -4.1% | ||
| Q3 25 | 6.1% | -2.2% | ||
| Q2 25 | 9.3% | -4.9% | ||
| Q1 25 | 6.5% | -18.6% | ||
| Q4 24 | 6.4% | -0.2% | ||
| Q3 24 | 12.4% | 0.3% | ||
| Q2 24 | 5.6% | -12.4% | ||
| Q1 24 | 4.6% | -15.2% |
每股收益（稀释后）BAHBLCO
| Q4 25 | $1.63 | $-0.16 | ||
| Q3 25 | $1.42 | $-0.08 | ||
| Q2 25 | $2.16 | $-0.18 | ||
| Q1 25 | $1.52 | $-0.60 | ||
| Q4 24 | $1.45 | $-0.00 | ||
| Q3 24 | $3.01 | $0.01 | ||
| Q2 24 | $1.27 | $-0.43 | ||
| Q1 24 | $0.97 | $-0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $882.0M | $383.0M |
| 总债务越低越好 | $3.9B | $5.0B |
| 股东权益账面价值 | $1.0B | $6.4B |
| 总资产 | $7.1B | $14.0B |
| 负债/权益比越低杠杆越低 | 3.84× | 0.78× |
8季度趋势，按日历期对齐
现金及短期投资BAHBLCO
| Q4 25 | $882.0M | $383.0M | ||
| Q3 25 | $816.0M | $310.0M | ||
| Q2 25 | $711.0M | $266.0M | ||
| Q1 25 | $885.0M | $202.0M | ||
| Q4 24 | $453.5M | $305.0M | ||
| Q3 24 | $558.7M | $329.0M | ||
| Q2 24 | $297.7M | $285.0M | ||
| Q1 24 | $554.3M | $315.0M |
总债务BAHBLCO
| Q4 25 | $3.9B | $5.0B | ||
| Q3 25 | $4.0B | $5.0B | ||
| Q2 25 | $4.0B | $5.0B | ||
| Q1 25 | $4.0B | $4.8B | ||
| Q4 24 | $3.4B | $4.8B | ||
| Q3 24 | $3.4B | $4.6B | ||
| Q2 24 | $3.4B | $4.6B | ||
| Q1 24 | $3.4B | $4.6B |
股东权益BAHBLCO
| Q4 25 | $1.0B | $6.4B | ||
| Q3 25 | $996.0M | $6.4B | ||
| Q2 25 | $1.1B | $6.4B | ||
| Q1 25 | $1.0B | $6.4B | ||
| Q4 24 | $1.2B | $6.5B | ||
| Q3 24 | $1.2B | $6.6B | ||
| Q2 24 | $1.1B | $6.5B | ||
| Q1 24 | $1.0B | $6.7B |
总资产BAHBLCO
| Q4 25 | $7.1B | $14.0B | ||
| Q3 25 | $7.2B | $13.8B | ||
| Q2 25 | $7.2B | $13.8B | ||
| Q1 25 | $7.3B | $13.4B | ||
| Q4 24 | $6.8B | $13.5B | ||
| Q3 24 | $6.9B | $13.5B | ||
| Q2 24 | $6.6B | $13.3B | ||
| Q1 24 | $6.6B | $13.3B |
负债/权益比BAHBLCO
| Q4 25 | 3.84× | 0.78× | ||
| Q3 25 | 3.98× | 0.77× | ||
| Q2 25 | 3.74× | 0.77× | ||
| Q1 25 | 3.99× | 0.76× | ||
| Q4 24 | 2.79× | 0.74× | ||
| Q3 24 | 2.83× | 0.70× | ||
| Q2 24 | 3.14× | 0.71× | ||
| Q1 24 | 3.26× | 0.69× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $261.0M | $136.0M |
| 自由现金流经营现金流 - 资本支出 | $248.0M | $60.0M |
| 自由现金流率自由现金流/营收 | 9.5% | 4.3% |
| 资本支出强度资本支出/营收 | 0.5% | 5.4% |
| 现金转化率经营现金流/净利润 | 1.30× | — |
| 过去12个月自由现金流最近4个季度 | $933.4M | $-66.0M |
8季度趋势，按日历期对齐
经营现金流BAHBLCO
| Q4 25 | $261.0M | $136.0M | ||
| Q3 25 | $421.0M | $137.0M | ||
| Q2 25 | $119.0M | $35.0M | ||
| Q1 25 | $219.0M | $-25.0M | ||
| Q4 24 | $150.8M | $22.0M | ||
| Q3 24 | $587.1M | $154.0M | ||
| Q2 24 | $52.1M | $15.0M | ||
| Q1 24 | $143.8M | $41.0M |
自由现金流BAHBLCO
| Q4 25 | $248.0M | $60.0M | ||
| Q3 25 | $395.0M | $63.0M | ||
| Q2 25 | $96.0M | $-54.0M | ||
| Q1 25 | $194.4M | $-135.0M | ||
| Q4 24 | $133.6M | $-70.0M | ||
| Q3 24 | $563.3M | $94.0M | ||
| Q2 24 | $19.7M | $-57.0M | ||
| Q1 24 | $127.6M | $-26.0M |
自由现金流率BAHBLCO
| Q4 25 | 9.5% | 4.3% | ||
| Q3 25 | 13.7% | 4.9% | ||
| Q2 25 | 3.3% | -4.2% | ||
| Q1 25 | 6.5% | -11.9% | ||
| Q4 24 | 4.6% | -5.5% | ||
| Q3 24 | 17.9% | 7.9% | ||
| Q2 24 | 0.7% | -4.7% | ||
| Q1 24 | 4.6% | -2.4% |
资本支出强度BAHBLCO
| Q4 25 | 0.5% | 5.4% | ||
| Q3 25 | 0.9% | 5.8% | ||
| Q2 25 | 0.8% | 7.0% | ||
| Q1 25 | 0.8% | 9.7% | ||
| Q4 24 | 0.6% | 7.2% | ||
| Q3 24 | 0.8% | 5.0% | ||
| Q2 24 | 1.1% | 5.9% | ||
| Q1 24 | 0.6% | 6.1% |
现金转化率BAHBLCO
| Q4 25 | 1.30× | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | 0.44× | — | ||
| Q1 25 | 1.14× | — | ||
| Q4 24 | 0.81× | — | ||
| Q3 24 | 1.50× | 38.50× | ||
| Q2 24 | 0.32× | — | ||
| Q1 24 | 1.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BAH
| Defense Clients | $1.5B | 55% |
| Civil Clients | $732.0M | 28% |
| Intelligence Clients | $434.0M | 17% |
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
